Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, Barclays Analyst Says

Merck & Co., Inc. (NYSE:MRK) had its target price increased by analysts at Barclays from $140.00 to $150.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would suggest a potential upside of 13.77% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Guggenheim raised their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Bank of America boosted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, BMO Capital Markets upped their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $134.50.

Merck & Co., Inc. Stock Up 0.8%

MRK stock opened at $131.85 on Wednesday. The stock has a market capitalization of $325.64 billion, a price-to-earnings ratio of 37.14, a price-to-earnings-growth ratio of 5.19 and a beta of 0.19. The company has a 50-day moving average of $122.39 and a two-hundred day moving average of $118.10. Merck & Co., Inc. has a 52-week low of $76.66 and a 52-week high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current year.

Institutional Trading of Merck & Co., Inc.

A number of hedge funds have recently modified their holdings of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. during the fourth quarter worth $26,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new stake in Merck & Co., Inc. in the 4th quarter valued at $31,000. Finally, High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.